Ipsilateral Eyelid Disorders Following Ocular Brachytherapy.
Iodine-125 brachytherapy is linked to higher odds of eyelid drooping than ruthenium-106.
Ipsilateral Eyelid Disorders Following Ocular Brachytherapy.
While episcleral brachytherapy is an effective treatment for uveal melanoma, its long-term complications have primarily focused on intraocular structures.
This retrospective study aimed to assess the prevalence, characteristics, and risk factors for acquired ipsilateral eyelid disorders (ipsilateral eyelid disorders) after ocular brachytherapy.
A retrospective clinical cohort study was conducted on patients who underwent episcleral brachytherapy at a single tertiary center between 2009 and 2023.
iodine-125 patients had far higher odds of drooping eyelid afterward
All tumors were malignant melanoma: choroidal (n = 156, 81.7%), ciliary body (n = 27, 14.1%), iris (n = 7, 3.7%), and anterior segment (n = 1, 0.5%).
Isotopes used included Iodine-125 (n = 150, 78.5%) and Ruthenium-106 (n = 41, 21.5%).
Ipsilateral eyelid disorders developed in 40 cases (20.9%), predominantly affecting the upper eyelid.
Ptosis was significantly associated with anterior tumor location (p = 0.03), iodine isotope (p = 0.01), and female gender (p = 0.04).
Acquired eyelid disorders, particularly upper eyelid ptosis, are a relatively common and underrecognized complication following episcleral brachytherapy.
Increased awareness of these potential sequelae and timely referral to oculoplastic specialists are advised.